

## Webinar on IMI 2 – Call 18 ‘Accelerating research and innovation for advanced therapy medicinal products’

### Participant list

19.06.2019

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Ahmad	Alfaar	Charité Medical University Berlin	Germany	ahmadsfar@gmail.com	Medicine, ophthalmology, oncology, clinical research, medical informatics, project management
Inge	Andresen	Aarhus University	Denmark	ina@au.dk	Support service
Eileen	Arnold	Fraunhofer IGB	Germany	Eileen.Arnold@igb.fraunhofer.de	Research and development of ATMPs (viral therapeutics, virus engineering and production)
Ana	Bejanariu	ISTEM	France	abejanariu@istem.fr	Experience in ATMP production, down to large scale, experience in in vivo preclinical assays.
Alexis	Bemelmans	CEA	France	alexis.bemelmans@cea.fr	intracerebral gene transfer and immune response in non-human primates
Stefano	Benvenuti	Fondazione Telethon	Italy	sbenvenuti@telethon.it	Experience in ATMP development up to market - Fondazione Telethon is the developer
Riccardo	Bertini	Innovation ACTA S.r.l.	Italy	bertini@innovationacta.eu	Project management, Dissemination and Communication activities

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Monika	Bogiel	Institute of Biotechnology and Antibiotics	Poland	bogielm@iba.waw.pl	R&D of biopharmaceutics
MARTA	BURGOS GONZALEZ		Spain	proyectos@parkinsonmadrid.org	End user needs, co- creation, patients' empowerment, mock ups and prototype validation. Patients, caregivers and social health
Johannes	Christiaans	Tartu University	Estonia	hans.christiaans@ut.ee	Medicinal Chemistry expertise to develop new drugs and radiopharmaceuticals. Access to GMP lab for precursor tracer synthesis
Cristina	Cuscó		Spain	cristina.cusco@vhir.org	Offering the research staff with the most suitable opportunities in their field of expertise
Veronique	Daniels	KU Leuven	Belgium	veronique.daniels@kuleuven.be	PET imaging (clinical and pre-clinical), PET tracer development, viral vector expertise and technology, patient cohorts
Marieke	De Bruin	Copenhagen Centre for Regulatory Science	Denmark	marieke.debruin@sund.ku.dk	Regulatory Science, Advanced Therapies regulation in different jurisdictions (landscape analysis), Authorisation pathways
Erica	Delucchi	CRG		erica.delucchi@crg.eu	Biomedical research
Lauranne	Duquenne	NeurATRIS	France	lauranne.duquenne@cea.fr	preclinical (rodent and primate) expertise in gene and cell therapies, AAV production

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Natalia	Elizalde	VIVEbiotech	Spain	nelizalde@vivebiotech.com	We are a Company fully specialized in Lentiviral vectors developing safer and more cost-effective processes.
Kåre	Engkilde	Longboat Amniotics	Sweden	ke@longboatamniotics.com	experience in working with mesenchymal stem cells along with GMP production
Astrid	Flandorfer	FFG	Austria	astrid.flandorfer@ffg.at	
Giovanna	Frazziano	FONDAZIONE Ri.MED	Italy	gfrazziano@fondazionerimed.com	Expertise in cell and molecular biology. Expertise in GMP production and Quality control for ATMPs. Regulatory knowledge
Michela	Gabaldo	RESTORE / Fondazione Telethon	Italy	mgabaldo@telethon.it	ATMP development & market access
Matteo	Gabetta	BIOMERIS	Italy	matteo.gabetta@biomeris.it	i2b2, OMOPO/OHDSI, Data integration, Data harmonization, ETL, Natural Language Processing, NLP, Wearable Sensors, REDCap
Simona	Giardina	Barcelona Supercomputing Center	Spain	simona.giardina@bsc.es	Computational and Bioinformatics

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Oscar	Gonzalez	Clinica Universidad de Navarra	Spain	ogonmor@unav.es	We have an Adoptive Cell Therapy research program which includes CAR-T from bench to bed-side, along with a GMP lab
Gloria	Gonzalez-Aseguinolaza	CIMA University of Navarra	Spain	ggasegui@unav.es	Therapeutic vector design, preclinical studies in Animal models (mice, NHP), Immune response analysis (Cellular and humoral)
David	Gross	INSERM	France	david.gross@inserm.fr	Dedicated academic team with expertise on immune response after rAAV-mediated gene transfer and tolerance induction.
David	Ibañez	Starlab	Spain	david.ibanez@starlab.es	Experience in data analysis, machine learning, signal processing, application development, hardware and application development
Angelica	Intini	TEDDY Network	Italy	scientificsecretariat@teddynetwork.net	Paediatric expertise
Zoltan	Ivics	Paul Ehrlich Institute	Germany	zoltan.ivics@pei.de	Non-viral gene therapy
Pall	Jonsson	NICE	United Kingdom	pall.jonsson@nice.org.uk	Assessment of ATMPs, IMI projects, H2020 projects, Health technology assessments, regulator and payer engagements.

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Aino	Kalervo	TILT Biotherapeutics	Finland	aino@tiltbio.com	TILT Biotherapeutics could bring expertise related to development of ATMPs, oncolytic immunotherapy and T-cell therapy.
Susan	Kentner	German Cancer Research Center (DKFZ)	Germany	s.kentner@dkfz.de	The DKFZ Grants Office supports its scientists in applying for third-party funding and in administering projects.
Sándor	Kovács	Syreon Research Institute (SRI)	India	sandor.kovacs@syreon.eu	Transferability of research findings into CEE countries; Cost-effectiveness analysis of gene therapies; Equity in patient access
Paul	Leonard	Dublin City University	Ireland	paul.leonard@dcu.ie	Patented digital cell biology platform called DiCAST that can analyse millions of single cells in parallel.
Bernard	Maillere	CEA, University of Paris Saclay	France	bernard.maillere@cea.fr	I am expert in immunogenicity prediction especially of therapeutic proteins. I was part of ABIRISK.
Cinzia	Marianelli	Istituto Superiore di Sanità	Italy	cinzia.marianelli@iss.it	Developing of alternatives to treat animal diseases and human autoimmune diseases
Sofie	Meerschaut	Modis	Belgium	sofie.meerschaut@modisbelgium.be	Proposal writing/coordination, project management, consortium management
Tanja	Miletic	AIT, Austrian Institute of Technology	Austria	tanja.miletic@ait.ac.at	Project management

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Rebecca	Moore	European Institute of Women's Health	Ireland	moorerm@tcd.ie	Gender equity, public health, health promotion, health equality, women's health, Research, advocacy, communications
Sterghios	Moschos	Northumbria University	United Kingdom	sterghios.moschos@northumbria.ac.uk	Predictive pharmacogenomics, virus QA/QC methods, pan-omics biomarker discovery, point of need NAAT testing.
Bertalan	Nemeth	Syreon Research Institute	Hungary	bertalan.nemeth@syreon.eu	Experience from other EU-funded projects, expertise in health policy, HTA, statistics, modelling, and transferability research
Catarina	Neves	CINTESIS - Center for Health Technology and Services Research	Portugal	catarinamneves@med.up.pt	CINTESIS is a research unit with a health research scope (www.cintesis.eu) at the Faculty of Medicine of the UPorto.
Karolina	Niewola			k.niewola@ionctura.com	Scientific expertise, a new cancer/fibrosis therapeutic, coordination
Racheli	Ofir		Israel	racheli@pluristem.com	late stage clinical stage placenta derived cellular therapy
FATMA VISAL	OKUR	HACETTEPE UNIVERSITY	Turkey	fvokur@hacettepe.edu.tr	To transport new technology into Turkey and develop standards for application of ATMPs
Nawal	Ouzren			nawal.ouzren@sensorn-pharma.com	Gene Therapy development

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Paul	Peeters			paul.peeters@modisbelgium.be	life sciences consultants experienced in drug development, product marketing and patient care
CECILE	PELTEKIAN	Isntitut Pasteur	France	cecile.peltekian@pasteur.fr	Expertise on chemogenomics etc...
PAULA	Petrone	Health Catalyst	Spain	petronepau@healthcatalyst.com	Clinical data warehousing, real world data from 120M+ patients, data science and analytics expertise
Isabelle	Philippe	CEA	France	isabelle.philippe@cea.fr	Expertise in immunogenicity
Angela	Ponce Polo	Andalusian Network for Design And Translation of Advanced Therapies	Spain	angela.ponce@juntadeandalucia.es	Preclinical expertise, clinical development, GMP manufacturing, regulatory, exploitation and dissemination
Severine	Pouillot	Genethon	France	spouillot@genethon.fr	expertise in gene therapy, from design and proof of concept of biotherapeutics, to clinical trial
Tristan	Pritchard-Meaker	Cell and Gene Therapy Catapult	United Kingdom	tristan.pritchard-meaker@ct.catapult.org.uk	Cell and gene therapy industrialisation support including development laboratories and consultancy resources
Vaclovas	Radvilas	ZeClinics SL	Spain	vaclovas.radvilas@zeclinics.com	CRISPR/Cas9-mediated zebrafish modelling

Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
Doris	Rakoczy	AIT Austrian Institute of Technology GmbH	Austria	doris.rakoczy@ait.ac.at	biosensors, systems integration, point-of-care devices, bioinformatics, biomarker discovery & validation, biological barriers...
Miria	Ricchetti	Institut Pasteur	France	mricch@pasteur.fr	patented therapy for a rare disease
Álvaro	Ritoré Hidalgo	Andalusian Network for Design and Traslation of Advanced Therapies	Spain	alvaro.ritore@juntadeandalucia.es	Preclinical expertise, Clinical development, Manufacturing capacities
Giuseppe	Ronzitti	Genethon	France	gronzitti@genethon.fr	Expertise in AAV immunology and AAV gene therapy
Elena	Serena	Genething s.r.l.	Italy	elena.serena@gmail.com	Expertise in Gene Therapy
Sara	Skogsater	ARTTIC	France	skogsater@arttic.eu	Project management, communication, dissemination, training, preparation of the exploitation of results
Frauke	Stähler	RESTORE	Germany	frauke.staehler@charite.de	RESTORE aims to cure chronic diseases by making the transformative promise of Advanced Therapies reality for patients benefit
Gabriele	Thumann	University	Switzerland	gabriele.thumann@unige.ch	cell based, non-viral gene therapy



Name	Surname	Organisation	Country	e-mail address	Briefly, what would you bring to the project in terms of expertise, resources, and activities?
D.B.R.K. Gupta	Udatha	Oslo Cancer Cluster	Norway	gupta.udatha@oslocancercluster.no	Cluster Network, SME Innovation, Academic and Clinician Groups, Event Management, Communication, Dissemination, Exploitation
Andrei	Valcea	Umf Carol Davila	Romania	andrei.a.valcea@gmail.com	Create bridge between clinical studies and AI!
David	Vanneste	University of Barcelona	Spain	davidvanneste@ub.edu	Expertise on ATMP R&D for neurodegenerative disorders
Silvia	Vanni	SISSA	Italy	svanni@sissa.it	In our lab we extensively investigate different cell line models for prion and prion-like diseases
Raymond	Verhaert	ProteoNic	Netherlands	verhaert@proteonic.nl	Production of biopharmaceutical proteins, biological medicines: production cell line development, production (improvement)
Alessandra	Veronese		Italy	veronal2710@gmail.com	Strong knowledge of drugs and medical devices development, long term experience as caregiver for Parkinson and Cancer patients.
Mary	Wang		Italy	mwang@telethon.it	gene therapy, vectors, GLP
Lena	Wiese	L3S Research Center / Fraunhofer ITEM	Germany	wiese@l3s.de	Computer Science, Artificial Intelligence
Anna	Williams	Cell and gene therapy catapult	United Kingdom	anna.williams@ct.catapult.org.uk	ATMP's, development, manufacture, QC assays, preclinical, clinical, regs etc